$12.16
0.08% yesterday
NYSE, Oct 21, 10:00 pm CET
ISIN
US04635X1028
Symbol
ATXS

Astria Therapeutics Stock price

$12.16
+4.65 61.92% 1M
+8.05 195.86% 6M
+3.22 36.02% YTD
+0.90 7.99% 1Y
+2.63 27.60% 3Y
-20.30 62.54% 5Y
-412.04 97.13% 10Y
-767.84 98.44% 20Y
NYSE, Closing price Tue, Oct 21 2025
+0.01 0.08%
ISIN
US04635X1028
Symbol
ATXS
Industry

Key metrics

Basic
Market capitalization
$686.3m
Enterprise Value
$427.1m
Net debt
positive
Cash
$259.2m
Shares outstanding
56.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 49.2
EV/Sales
- | 30.6
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
93.3%
Return on Equity
-29.5%
ROCE
-49.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $13.9m
EBITDA
- | $-162.3m
EBIT
$-131.4m | $-138.0m
Net Income
$-116.9m | $-119.7m
Free Cash Flow
$-116.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-22.4% | -23.7%
Net Income
-25.4% | -26.9%
Free Cash Flow
-43.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,164.2%
EBIT
-
Net
- | -858.3%
Free Cash Flow
-
More
EPS
$-2.0
FCF per Share
$-2.1
Short interest
6.9%
Employees
78
Rev per Employee
$0.0
Show more

Is Astria Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,002 stocks worldwide.

Astria Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Astria Therapeutics forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Astria Therapeutics forecast:

Buy
93%
Hold
7%

Financial data from Astria Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 37 37
20% 20%
-
- Research and Development Expense 94 94
23% 23%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -131 -131
22% 22%
-
Net Profit -117 -117
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Astria Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Astria Therapeutics Stock News

Neutral
Business Wire
5 days ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash and 0.5...
Neutral
GlobeNewsWire
7 days ago
NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Neutral
PRNewsWire
8 days ago
MILWAUKEE , Oct. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Astria (NASDAQ: ATXS) for possible breaches of fiduciary duty and other violations of law in its transaction with BioCryst. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
More Astria Therapeutics News

Company Profile

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jill Milne
Employees 78
Founded 2008
Website astriatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today